XNAS · Healthcare · Biotechnology
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q1 2027 | -0.37 | -0.34 | +8.11% | $1.4M | ✅ Beat | +1.16% | +3.30% | — |
| 2026-05-20 | Q4 2026 | -0.36 | -0.27 | +23.89% | $2.5M | ✅ Beat | -0.11% | -8.73% | -3.02% |
| 2026-02-06 |
| Q3 2026 |
| -0.34 |
| -0.24 |
| +29.41% |
| $2.0M |
| ✅ Beat |
| -0.90% |
| +2.44% |
| +14.37% |
| 2025-11-10 | Q2 2026 | -0.32 | -0.28 | +12.50% | $1.6M | ✅ Beat | — | — | — |
| 2025-08-11 | Q1 2026 | -0.26 | -0.25 | +3.85% | $2.2M | ✅ Beat | -4.18% | +5.73% | +23.28% |
| 2025-02-10 | Q3 2025 | -0.24 | -0.20 | +16.67% | $9.0M | ✅ Beat | -2.78% | -1.02% | -1.76% |
| 2024-05-30 | Q4 2024 | -0.30 | -0.19 | +36.67% | $28.9M | ✅ Beat | -0.29% | +2.21% | +4.23% |
| 2024-02-13 | Q3 2024 | -0.32 | -0.21 | +34.38% | $37.1M | ✅ Beat | — | — | — |
Showing last 8 quarters.